March 18, 2015
Agilvax Inc., a biotechnology company that develops vaccines and immunotherapies to combat infectious diseases and cancer, announced today that President & CEO, Federica Pericle, will attend the 12th Annual Bio Asia International Conference in Tokyo, Japan, March 24-25, 2015. Dr. Pericle will be available for one-on-one meetings, and welcomes the opportunity to discuss Agilvax’s novel vaccine / immunotherapy discovery and development platform.
Agilvax (www.agilvax.com) develops vaccines targeting infectious diseases and immunotherapies to combat cancer utilizing its proprietary virus-like particle (VLP) platform technology. The company has a pipeline and platform that is based on VLPs derived from RNA bacteriophage that have been engineered to incorporate novel peptide epitopes. The platform allows the company to rapidly identify ideal VLP candidates, moving from hypothesis to preclinical proof of concept in months. The Company was founded in 2011 and has headquarters in Albuquerque, NM, USA.
Federica Pericle, Ph.D., M.B.A.
President and Chief Executive Officer